[1] BAILEY P D, BOYD C A, COLLIER I D, et al. Conformational and spacial p for substrates of pept1[J]. Chem Commun (Camb, 2005, 14（42:5352-5354.
[2] BRODIN B, NIELSEN C U, STEFFANSEN B, et al. Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, pept1[J]. Pharmacol Toxicol, 2002, 90(6:285-296.
[3] KULKARNI A A, HAWORTH I S, UCHIYAMA T, et al. Analysis of transmembrane segment 7 of the dipeptide transporter hpept1 by cysteine-scanning mutagenesis[J]. J Biol Chem, 2003, 278(51:51833-51840.
[4] IRIE M, TERADA T, KATSURA T, et al. Computational modelling of H+-coupled peptide transport via human pept1[J]. J Physiol, 2005, 565(Pt 2:429-439.
[5] WATANABE K, JINRIKI T, SATO J. Effects of progesterone and norethisterone on cephalexin transport and peptide transporter pept1 expression in human intestinal cell line caco-2[J]. Biol Pharm Bull, 2006, 29(1:90-95.
[6] FISHER S J, LEE I J, SWAAN P W, et al. Evaluation of the effect of ethanol's toxic metabolite acetaldehyde on the gastrointestinal oligopeptide transporter, pept1: In vitro and in vivo studies[J]. Alcohol Clin Exp Res, 2008, 32(1:162-170.
[7] NDUATI V, YAN Y, DALMASSO G, et al. Leptin transcriptionally enhances peptide transporter (hpept1 expression and activity via the camp-response element-binding protein and cdx2 transcription factors[J]. J Biol Chem, 2007, 282(2:1359-1373.
[8] LU H, KLAASSEN C. Tissue distribution and thyroid hormone regulation of pept1 and pept2 mrna in rodents[J]. Peptides, 2006, 27(4:850-857.
[9] TSUDA M, TERADA T, IRIE M, et al. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives[J]. J Pharmacol Exp Ther, 2006, 318(1:455-460.
[10] THORN K, ANDERSEN R, CHRISTENSEN J, et al. Design, synthesis, and evaluation of tripeptidic promoieties targeting the intestinal peptide transporter hpept1[J]. Chem Med Chem, 2007, 2(4:479-487.
[11] MITSUOKA K, TAMAI I, MOROHASHI Y, et al. Direct evidence for efficient transport and minimal metabolism of l-cephalexin by oligopeptide transporter 1 in budded baculovirus fraction[J]. Biol Pharm Bull, 2009, 32(8:1459-1461.
[12] GEBAUER S, KNUTTER I, HARTRODT B, et al. Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter pept1[J]. J Med Chem, 2003, 46(26:5725-5734.
[13] BRANDSCH M, KNUTTER I, LEIBACH F H. The intestinal H+/peptide symporter pept1: Structure-affinity relationships[J]. Eur J Pharm Sci, 2004, 21(1:53-60.
[14] VIG B S, STOUCH T R, TIMOSZYK J K, et al. Human pept1 pharmacophore distinguishes between dipeptide transport and binding[J]. J Med Chem, 2006, 49(12:3636-3644.
[15] FOLEY D, BAILEY P, PIERI M, et al. Targeting ketone drugs towards transport by the intestinal peptide transporter, pept1[J]. Org Biomol Chem, 2009, 7(6:1064-1067.
[16] LI F, HONG L, MAU C I, et al. Transport of levovirin prodrugs in the human intestinal caco-2 cell line[J]. J Pharm Sci, 2006, 95(6:1318-1325.
[17] THEIS S, KNUTTER I, HARTRODT B, et al. Synthesis and characterization of high affinity inhibitors of the H+/peptide transporter pept2[J]. J Biol Chem, 2002, 277(9:7287-7292.
[18] PERKINS E J, ABRAHAM T. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (slc15a1-targeted prodrug (1s,2s,5r,6s-2-[(2's-(2-aminopropionyl]aminobicyclo[3.1.0.]hexen-2,6-di carboxylic acid (ly544344 in rats and dogs: Assessment of first-pass bioactivation and dose linearity[J]. Drug Metab Dispos, 2007, 35(10:1903-1909.
[19] KATRAGADDA S, TALLURI R S, MITRA A K. Modulation of p-glycoprotein-mediated efflux by prodrug derivatization: An approach involving peptide transporter-mediated influx across rabbit cornea[J]. J Ocul Pharmacol Ther, 2006, 22(2:110-120.
[20] BIEGEL A, GEBAUER S, HARTRODT B, et al. Recognition of 2-aminothiazole-4-acetic acid derivatives by the peptide transporters pept1 and pept2[J]. Eur J Pharm Sci, 2007, 32(1:69-76.
[21] BAILEY P D, BOYD C A, COLLIER I D, et al. Affinity prediction for substrates of the peptide transporter pept1[J]. Chem Commun (Camb, 2006, 21(3:323-325.
[22] ASHIDA K, KATSURA T, SAITO H, et al. Decreased activity and expression of intestinal oligopeptide transporter pept1 in rats with hyperthyroidism in vivo[J]. Pharm Res, 2004, 21(6:969-975.
[23] HINDLET P, BADO A, FARINOTTI R, et al. Long-term effect of leptin on H+-coupled peptide cotransporter 1 activity and expression in vivo: Evidence in leptin-deficient mice[J]. J Pharmacol Exp Ther, 2007, 323(1:192-201.
[24] VAVRICKA S R, MUSCH M W, FUJIYA M, et al. Tumor necrosis factor-alpha and interferon-gamma increase pept1 expression and activity in the human colon carcinoma cell line caco-2/bbe and in mouse intestine[J]. Pflugers Arch, 2006, 452(1:71-80.
[25] FOSTER D R, LANDOWSKI C P, ZHENG X, et al. Interferon-gamma increases expression of the di/tri-peptide transporter, h-pept1, and dipeptide transport in cultured human intestinal monolayers[J]. Pharmacol Res, 2009, 59(3:215-220.
[26] SHIMAKURA J, TERADA T, KATSURA T, et al. Characterization of the human peptide transporter pept1 promoter: Sp1 functions as a basal transcriptional regulator of human pept1[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 289(3: 471-477.
[27] OKAMURA M, TERADA T, KATSURA T, et al. Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats[J]. Drug Metab Pharmacokinet, 2008, 23(6:464-468.
[28] DALMASSO G, NGUYEN H T, YAN Y, et al. Butyrate transcriptionally enhances peptide transporter pept1 expression and activity[J]. PLoS One, 2008, 3(6:2476-2477.
[29] SHIMAKURA J, TERADA T, SAITO H, et al. Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291(5:851-856.
[30] INOUE M, TERADA T, OKUDA M, et al. Regulation of human peptide transporter 1 (pept1 in gastric cancer cells by anticancer drugs[J]. Cancer Lett, 2005, 230(1:72-80.
[31] RADEVA G, BUYSE M, HINDLET P, et al. Regulation of the oligopeptide transporter, pept-1, in dss-induced rat colitis[J]. Dig Dis Sci, 2007, 52(7:1653-1661.
[32] HINDLET P, BADO A, KAMENICKY P, et al. Reduced intestinal absorption of dipeptides via pept1 in mice with diet-induced obesity is associated with leptin receptor down-regulation[J]. J Biol Chem, 2009, 284(11:6801-6808.
[33] HANG C H, SHI J X, SUN B W, et al. Apoptosis and functional changes of dipeptide transporter (pept1 in the rat small intestine after traumatic brain injury[J]. J Surg Res, 2007, 137(1:53-60.
[34] FEI Y J, SUGAWARA M, LIU J C, et al. Cdna structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter pept1[J]. Biochim Biophys Acta, 2000, 1492(1:145-154.
[35] SHIMAKURA J, TERADA T, SHIMADA Y, et al. The transcription factor cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with sp1[J]. Biochem Pharmacol, 2006, 71(11:1581-1588.
[36] SAITO H, TERADA T, SHIMAKURA J, et al. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (pept1[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 295(2: 395-402.
[37] BALIMANE P V, CHONG S, PATEL K, et al. Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected mdck-hpept1 cells to caco-2 cells[J]. Arch Pharm Res, 2007, 30(4:507-518.